ArticleGlycobiology2008
Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies.
Article in Glycobiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 223 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
223 citing papers in PubMed, 5 syntheses or guidelines pooled it, 423 citations in OpenAlex.
- ABO blood group and risk of COVID-19 infection and complications: A systematic review and meta-analysis.Transfusion · 2022Pooled it
- Systematic review and meta-analysis of the susceptibility of ABO blood group to COVID-19 infection.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Pooled it
- The impact of ABO blood group on COVID-19 infection risk and mortality: A systematic review and meta-analysis.Blood reviews · 2021Pooled it
- The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review.Virus research · 2020Pooled it
- Association between ABO blood groups and COVID-19 infection, severity and demise: A systematic review and meta-analysis.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Pooled it
- Assessment of severity and mortality of COVID-19 with anti-A1 and anti-B IgM isohaemagglutinins, a reflection of the innate immune status.International journal of clinical practice · 2021Trial
- Association between ABO and Duffy blood types and circulating chemokines and cytokines.Genes and immunity · 2021Trial
- The impact of ABO blood groups on clinical outcomes and susceptibility to COVID-19: A retrospective study in an unselected population.Transfusion · 2021Trial
- Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.Journal of internal medicine · 2021Trial
- ABO blood type association with SARS-CoV-2 infection mortality: A single-center population in New York City.Transfusion · 2021Trial
- ABO phenotype and death in critically ill patients with COVID-19.British journal of haematology · 2020Trial
- A narrative review of the epidemiological and mechanistic associations between ABO blood groups and diseases: focusing on cardiovascular diseases, cancers, diabetes, malaria, COVID-19 and rheumatic diseases.Annals of medicine · 2026Review
- Impact of ABO Blood System on Immunogenicity and Vaccine Efficacy of COVID-19 Booster Vaccination-A Population-Based Study of 3066 Individuals.Influenza and other respiratory viruses · 2026Article
- Association between ABO blood groups and clinical manifestations and outcomes of COVID-19: a retrospective cross-sectional study in southeast Iran.Scientific reports · 2026Article
- Molecular detection and low prevalence of Human Herpesvirus 6 (HHV-6) among male blood donors in Kassala, Sudan: a preliminary single-center study.BMC research notes · 2026Article
- Integrating Host Genetics and Clinical Setting in Machine Learning Models: Predicting COVID-19 Prognosis for Healthcare Decision-Making (The FeMiNa Study).Diagnostics (Basel, Switzerland) · 2026Article
- Host Glycan-Lectin Interplay in SARS-CoV-2 Infection.International journal of molecular sciences · 2026Review
- The AB Blood Group System Phenotype Does Not Play a Role inPathogens (Basel, Switzerland) · 2025Article
- Blood Group Type and COVID-19 Severity at Tertiary Care Centre, Nepal: An Observational Study.JNMA; journal of the Nepal Medical Association · 2025Observational
- ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.PloS one · 2025Article
163 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) is a highly pathogenic emergent virus which replicates in cells that can express ABH histo-blood group antigens. The heavily glycosylated SARS-CoV spike (S) protein binds to angiotensin-converting enzyme 2 which serves as a cellular receptor. Epidemiological analysis of a hospital outbreak in Hong Kong revealed that blood group O was associated with a low risk of infection. In this study, we used a cellular model of adhesion to investigate whether natural antibodies of the ABO system could block the S protein and angiotensin-converting enzyme 2 interaction. To this aim, a C-terminally EGFP-tagged S protein was expressed in chinese hamster ovary cells cotransfected with an alpha1,2-fucosyltransferase and an A-transferase in order to coexpress the S glycoprotein ectodomain and the A antigen at the cell surface. We observed that the S protein/angiotensin-converting enzyme 2-dependent adhesion of these cells to an angiotensin-converting enzyme 2 expressing cell line was specifically inhibited by either a monoclonal or human natural anti-A antibodies, indicating that these antibodies may block the interaction between the virus and its receptor, thereby providing protection. In order to more fully appreciate the potential effect of the ABO polymorphism on the epidemiology of SARS, we built a mathematical model of the virus transmission dynamics that takes into account the protective effect of ABO natural antibodies. The model indicated that the ABO polymorphism could contribute to substantially reduce the virus transmission, affecting both the number of infected individuals and the kinetics of the epidemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.